{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-029819","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2025-09-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.550757+00:00","generated_at":"2026-05-17T05:47:42.713575+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Monopar raises ~$91.9M net in offering; Wilson disease data published in Journal of Hepatology","bullets":["Offering of 1,034,433 shares at $67.67 and 960,542 pre-funded warrants at $67.669.","Net proceeds of ~$91.9M after deducting underwriting discounts and before expenses.","Agreed to repurchase 550,229 shares from Tactic Pharma (CEO's entity) at $63.6098 per share.","Journal of Hepatology letter shows ALXN1840 improved copper balance (p=0.005) in Wilson disease patients.","Offering expected to close September 25, 2025; share repurchase promptly thereafter."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-029819","json":"https://secwatch.observer/filing/0001437749-25-029819.json","markdown":"https://secwatch.observer/filing/0001437749-25-029819.md","text":"https://secwatch.observer/filing/0001437749-25-029819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925029819/0001437749-25-029819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925029819/mnpr20250924_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:47:42.713575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}